Sophia Genetics Sa's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Sophia Genetics Sa (SOPH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Sophia Genetics Sa vs Its Competitors
- TTM: Trailing 12-month revenue of 77M vs 11,951M combined for tracked competitors (0.6% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+2.7%) for its tracked peer group.
- Growth: Sophia Genetics Sa generated 18.7% revenue growth year over year in Q4 2025, vs 19.2% for its tracked competitors combined.
- Profitability: Its -102.5% net margin compares with 4.7% for the peer group.
- Scale: Sophia Genetics Sa ranks #68 of 165 companies by market capitalization in the Cloud Computing & Data Analytics industry, holding 0.1% of industry market cap.
- Peer revenue share: Sophia Genetics Sa accounted for 2.5% of combined revenue among its tracked peer group, down from 2.5% a year earlier.
- Peer differentiation: Revenue per employee of $1.51M compares with $0.65M for the peer group (2.3x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SOPH Sales vs. its Competitors, Q4 2025
Sophia Genetics Sa reported revenue growth of 18.70 % year on year in Q4 2025, below its competitors' combined revenue growth of 19.22 %.
With a net margin of -102.49 %, Sophia Genetics Sa reported lower profitability than its competitors (4.67 %).
Sophia Genetics Sa generated 2.45 % of the combined sales of its peer group, down from 2.46 % a year earlier.
Sophia Genetics Sa vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Sophia Genetics Sa and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Sophia Genetics Sa | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Sophia Genetics Sa's competitor groups requires a Commercial License.
For context: the Cloud Computing & Data Analytics industry grew revenue 8.2% year over year, combined, vs 18.7% for Sophia Genetics Sa. Sophia Genetics Sa's share of combined industry revenue moved from 0.05% to 0.06%, a gain of 0.00 percentage points.
Sophia Genetics Sa's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Sophia Genetics Sa | - | Yes | Yes | No |
| Competitors combined (5) | ||||
| High-Confidence Competitors (6) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SOPH Stock Performance relative to its Competitors
SOPH Stock Performance relative to High-Confidence Competitors
SOPH Stock Performance relative to Similar-Size Competitors
SOPH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Illumina Inc | 282.9% | Outperformed |
| 2 | Guardant Health Inc | 282.9% | Outperformed |
| 3 | Natera Inc | 282.9% | Outperformed |
| 4 | Exact Sciences Corporation | 282.9% | Outperformed |
| 5 | Fulgent Genetics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Sophia Genetics Sa's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Sophia Genetics Sa's Comment on Competition and Industry Peers
Publicly Traded Peers of Sophia Genetics Sa
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Sophia Genetics Sa | 565.98 | 77.08 |
| Natera Inc | 59,218.64 | 2,707.08 |
| Illumina Inc | 41,873.04 | 4,493.00 |
| Guardant Health Inc | 23,698.16 | 1,183.11 |
| Exact Sciences Corporation | 19,599.02 | 3,245.31 |
| Fulgent Genetics Inc | 616.67 | 322.97 |
| SUBTOTAL | 145,571.52 | 12,028.54 |
Sources: Sophia Genetics Sa's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Sophia Genetics Sa versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Sophia Genetics Sa's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Caris Life Sciences | Named by the company | 85% |
| Foundation Medicine, Inc. | Named by the company | 85% |
| Qiagen Digital Insights | Named by the company | 85% |
| Fabric Genomics | Named by the company | 85% |
| Koninklijke Philips | Named by the company | 85% |
| Thermo Fisher | Named by the company | 85% |
| Congenica Ltd | Named by the company | 85% |
| Illumina | Named by the company | 85% |
| Siemens | Named by the company | 85% |
| Agilent | Named by the company | 85% |
| Flatiron Health, Inc. | Named by the company | 85% |
| PierianDx, Inc. | Named by the company | 85% |
| Velsera | Named by the company | 85% |
| F. Hoffmann-La Roche | Named by the company | 85% |
| Konika Minolta | Named by the company | 85% |
| Tempus Labs | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Sophia Genetics Sa's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Sophia Genetics Sa's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Natera Inc | Reportable 100.00 % |
| Illumina Inc | Sequencing 90.94 % |
| Guardant Health Inc | Reportable 100.00 % |
| Fulgent Genetics Inc | Precision Diagnostics 57.08 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sophia Genetics Sa's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Sophia Genetics Sa | 566 | 1,511,314 | -1,549,000 |
| Natera Inc | 59,219 | 440,892 | -31,327 |
| Illumina Inc | 41,873 | 3,510,156 | 644,531 |
| Guardant Health Inc | 23,698 | 472,109 | -180,940 |
| Exact Sciences Corporation | 19,599 | 450,738 | -28,882 |
| Fulgent Genetics Inc | 617 | 240,307 | -63,593 |
| PEERS TOTAL | 145,006 | 647,074 | -6,183 |
Sophia Genetics Sa's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Natera Inc | United States 98.24 % |
| Illumina Inc | United States and Canada 56.34 % |
| Guardant Health Inc | United States 94.35 % |
| Exact Sciences Corporation | United States 93.11 % |
| Fulgent Genetics Inc | Other countries 4.93 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sophia Genetics Sa's Position in Industry Market Structure
Market-capitalization share and concentration across all 148 companies in Sophia Genetics Sa's industry classification, broader than the peer set above. Market cap in millions of $.Sophia Genetics Sa ranks #68 of 148 companies by market capitalization in its industry, holding 0.09 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 547, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Automatic Data Processing Inc | 104,076 | 16.74 % |
| 2 | Workday Inc | 46,912 | 7.55 % |
| 3 | Infosys Limited | 44,332 | 7.13 % |
| 4 | Zscaler Inc | 31,951 | 5.14 % |
| 5 | Reddit Inc | 1,234 | 5.2% |
| 6 | Cognizant Technology Solutions Corporation | 1,234 | 5.2% |
| 7 | Verisign Inc | 1,234 | 5.2% |
| 8 | Verisk Analytics Inc | 1,234 | 5.2% |
| 9 | Wipro Limited | 1,234 | 5.2% |
| 10 | Toast Inc | 1,234 | 5.2% |
| 68 | Sophia Genetics Sa | 564 | 0.09 % |
Market cap and industry share for the rest of Sophia Genetics Sa's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-30.
Sophia Genetics Sa's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 63 | Yext Inc | 667 | -23.26 % |
| 64 | Ibex Limited | 641 | 5.77 % |
| 65 | Ooma Inc | 590 | 72.66 % |
| 66 | Cars com Inc | 582 | -14.33 % |
| 67 | Nerdwallet Inc | 1,234 | 12.3% |
| 68 | Sophia Genetics Sa | 564 | 89.28 % |
| 69 | Veradigm Inc | 1,234 | 12.3% |
| 70 | Gravity co ltd | 1,234 | 12.3% |
| 71 | Ci and t Inc | 1,234 | 12.3% |
| 72 | Simulations Plus Inc | 1,234 | 12.3% |
| 73 | Kodiak Ai Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Sophia Genetics Sa's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-30. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Sophia Genetics Sa's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Cloud Computing & Data Analytics industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (202 companies). See the full Cloud Computing & Data Analytics industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 67.56 % | 51.77 % (avg) | +15.8 pp |
| Operating Margin | -91.99 % | industry median | -94.2 pp |
| EBITDA Margin | -89.47 % | 2.99 % (avg) | -92.5 pp |
| Capital Intensity (Capex / Revenue) | 0.74 % | 5.27 % (avg) | -4.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Sophia Genetics Sa's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | 30.18 % | 4.88 % | 18.70 % |
| Operating Margin | - | - | -91.99 % |
| Return on Invested Capital | -23.18 % | -29.44 % | -44.30 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Sophia Genetics Sa's Strategic Group Map
Every company in Sophia Genetics Sa's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Sophia Genetics Sa is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Sophia Genetics Sa's BCG Growth-Share Matrix
Relative market share (vs Sophia Genetics Sa's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Sophia Genetics Sa falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 5.4% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Sophia Genetics Sa's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 547 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.74 % vs industry average 5.27 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Sophia Genetics Sa's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Sophia Genetics Sa's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Sophia Genetics Sa's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Sophia Genetics Sa falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Sophia Genetics Sa's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 94.2 points below the industry median.
- Return on equity 181.9 points below the industry aggregate.
- Low relative market share vs the industry leader (0.01x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Sophia Genetics Sa's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Sophia Genetics Sa | 1.39 | 1.96 | 1.03 |
| Natera Inc | - | 3.14 | 0.05 |
| Illumina Inc | - | 1.74 | 0.75 |
| Guardant Health Inc | 2.56 | 4.29 | - |
| Exact Sciences Corporation | 1.22 | 2.68 | 0.95 |
| Fulgent Genetics Inc | 0.68 | 6.24 | 0.00 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Sophia Genetics Sa's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Sophia Genetics Sa | Q4 2025 | +18.7 % | - |
| Natera Inc | Q2 2026 | +37.7 % | - |
| Illumina Inc | Q2 2026 | +9.4 % | -11.9 % |
| Guardant Health Inc | Q2 2026 | +44.3 % | - |
| Exact Sciences Corporation | Q4 2025 | +23.1 % | - |
| Fulgent Genetics Inc | Q2 2026 | +4.9 % | - |
| PEERS TOTAL | +21.9 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Sophia Genetics Sa's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Sophia Genetics Sa | Q4 2025 | +18.6 % | +135.2 % |
| Natera Inc | Q2 2026 | -99.3 % | +144.9 % |
| Illumina Inc | Q2 2026 | +6.9 % | +33.3 % |
| Guardant Health Inc | Q2 2026 | +42.8 % | +108.2 % |
| Exact Sciences Corporation | Q4 2025 | +19.5 % | - |
| Fulgent Genetics Inc | Q2 2026 | +27.0 % | -43.5 % |
Sophia Genetics Sa's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Sophia Genetics Sa | - | - | - |
| Natera Inc | - | - | - |
| Illumina Inc | 12.68% | 19.61% | 31.08% |
| Guardant Health Inc | - | - | - |
| Exact Sciences Corporation | - | - | - |
| Fulgent Genetics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Sophia Genetics Sa's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Sophia Genetics Sa | - | 7.34 |
| Natera Inc | - | 21.88 |
| Illumina Inc | 51.25 | 9.32 |
| Guardant Health Inc | - | 20.03 |
| Exact Sciences Corporation | - | 6.04 |
| Fulgent Genetics Inc | - | 1.91 |
| PEERS AVERAGE | - | 12.10 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.